Towards Tris(diimine)–Ruthenium(II) and Bis(quinoline)–Re(I)(CO)3 Complexes as Photoactivated Anticancer Drug Candidates

The clinical success of cisplatin continues to inspire the development of metal-based anticancer drug candidates. This article is meant to present the current state-of-the-art and science of ruthenium(II)- and rhenium(I)-based anticancer drug candidates born out of our work in this field. Our recent efforts to elicit photoactivation of intact (organo)metallic anticancer drug candidates as a promising way for commanding their activity within cancer cells are also briefly summarized. 1 Introduction 2 Ruthenium(II) Complexes 3 Rhenium(I) Complexes 4 Concluding Remarks